Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00363857 · ClinicalTrials.gov registry record · Phase 3
A Clinical Research Study Testing Ropinirole Treatment for Restless Legs Syndrome
A Phase 3 study of Restless Legs Syndrome and Restless Legs Syndrome (RLS), sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 360
- Enrollment target
- 20
- Study locations
NCT00363857 is a Phase 3 study of Restless Legs Syndrome and Restless Legs Syndrome (RLS) that has completed, run by GlaxoSmithKline. The registered enrollment target is 360 participants, above the 71-participant average among 14 other Restless Legs Syndrome trials with a reported enrollment target (407% higher). The trial reports 20 study locations across 7 states.
The verdict
NCT00363857, a Phase 3 study of Restless Legs Syndrome and Restless Legs Syndrome (RLS), has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 360 participants
- Enrollment target
- 20
- Study locations
Study Summary
A 14-Week clinical research study to compare the effectiveness and safety of ropinirole and placebo (an inactive sugar pill) in the treatment of patients with Restless Legs Syndrome (RLS) in the United States.
Conditions Studied
Interventions
- DRUG Ropinirole
Study Locations (20)
California
- GSK Investigational Site - Berkeley
- GSK Investigational Site - La Jolla
- GSK Investigational Site - Northridge
- GSK Investigational Site - Oxnard
- GSK Investigational Site - Redondo Beach
- GSK Investigational Site - Santa Monica
- GSK Investigational Site - Stanford
Alabama
- GSK Investigational Site - Alabaster
- GSK Investigational Site - Birmingham
- GSK Investigational Site - Jasper
- GSK Investigational Site - Tuscaloosa
Florida
- GSK Investigational Site - Boca Raton
- GSK Investigational Site - Largo
- GSK Investigational Site - Pembroke Pines
- GSK Investigational Site - St. Petersburg
Arizona
- GSK Investigational Site - Phoenix
- GSK Investigational Site - Phoenix
Arkansas
- GSK Investigational Site - Little Rock
Colorado
- GSK Investigational Site - Aurora
Connecticut
- GSK Investigational Site - Danbury
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 360 participants |
| Start Date | 2003-08 |
| Est. Completion | 2004-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00363857
The ClinicalTrials.gov registry entry for NCT00363857 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 360 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 71-participant average among 14 other Restless Legs Syndrome trials with a reported enrollment target (407% higher). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Restless Legs Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Ropinirole is the first listed.
NCT00363857 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Alabama, Florida.
Frequently Asked Questions
What is clinical trial NCT00363857 about?
NCT00363857 is a clinical study titled "A Clinical Research Study Testing Ropinirole Treatment for Restless Legs Syndrome". A 14-Week clinical research study to compare the effectiveness and safety of ropinirole and placebo (an inactive sugar pill) in the treatment of patients with Restless Legs Syndrome (RLS) in the United States.
What is the current status of trial NCT00363857?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 360 participants. The study started on 2003-08. Estimated completion is 2004-05.
What conditions does trial NCT00363857 study?
This clinical trial studies the following conditions: Restless Legs Syndrome, Restless Legs Syndrome (RLS).
What interventions are being tested in trial NCT00363857?
The interventions under investigation include: Ropinirole (DRUG).
Who is sponsoring clinical trial NCT00363857?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00363857 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Restless Legs Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Blood Changes After Exercise in Restless Legs Syndrome
RECRUITING · NA
-
Treating Leg Symptoms in Women With X-linked Adrenoleukodystrophy
ACTIVE NOT RECRUITING · Phase 4
-
Response to an Investigational Device in Patients With Restless Legs Syndrome
ACTIVE NOT RECRUITING · NA
-
A Post-Market Study for Long-Term Effectiveness and Safety of the NTX100 for RLS
ACTIVE NOT RECRUITING
-
Benefits of a Cannabidiolic Acid Topical Cream for the Treatment of Restless Leg Syndrome
ACTIVE NOT RECRUITING · Phase 1
-
A Study To Investigate The Effects Of End Stage Renal Disease And Hemodialysis On The Pharmacokinetics Of Ropinirole
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.